文献速递神经免疫

ATX-MS-1467免疫治疗16周对复发型多发性硬化的影响

Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.
PubMed 文献 · Neurology · 2018-02-21

两项开放标签试验评估ATX-MS-1467在复发型多发性硬化中的安全性、耐受性和疗效。研究1为多中心1b期安全性评价,比较皮内与皮下给药(43例);研究2为多中心2a期单臂试验(37例)。研究1队列1新发/持续T1钆增强病灶从基线至第16周显著减少,第48周恢复基线;研究2治疗期间T1钆增强病灶数显著减少且研究结束时仍减少。两项研究安全性结果无异常。

要点

  • 研究1队列1新发/持续T1钆增强病灶从基线至第16周显著减少,第48周恢复基线值。
  • 研究2治疗期间T1钆增强病灶数显著减少,研究结束时仍保持减少。
  • 相对缓慢的ATX-MS-1467滴定和较长足量皮内治疗期与钆增强病灶减少及治疗后持续效应相关。

核心结论

  • 相对缓慢的ATX-MS-1467滴定和较长足量皮内治疗期与钆增强病灶减少及治疗后持续效应相关。
  • 尚需进一步开展ATX-MS-1467的试验。

研究设计与样本

  • 研究1为多中心1b期安全性评价,比较皮内(队列1)与皮下(队列2)给药,共43例复发型多发性硬化成人受试者。
  • 研究2为多中心2a期单臂试验,纳入37例复发型多发性硬化成人受试者。

主要发现

  • 研究1队列1新发/持续T1钆增强病灶从基线至第16周显著减少,第48周恢复基线值。
  • 研究2治疗期间T1钆增强病灶数显著减少,研究结束时仍保持减少。
  • 两项研究安全性结果均无异常。

关键数值与推荐

  • 研究1两队列ATX-MS-1467剂量为25、50、100、400、800 μg,14天间隔,持续8周,随后8周再给4次800 μg(14天间隔),之后停药32周。
  • 研究2第1天皮内50 μg,第15天滴定至200 μg,第29天至800 μg,随后每两周给药800 μg持续16周,之后停药16周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess safety, tolerability, and efficacy of the antigen-specific immunotherapy ATX-MS-1467 in participants with relapsing multiple sclerosis using different treatment protocols to induce tolerance. METHODS: Two open-label trials in adult participants with relapsing multiple sclerosis were conducted. Study 1 was a multicenter, phase 1b safety evaluation comparing intradermal (i.d.) (cohort 1) with subcutaneous (cohort 2) administration in 43 participants. Both cohorts received ATX-MS-1467 dosed at 25, 50, 100, 400, and 800 μg at 14-day intervals over 8 weeks, followed by 8 weeks with 4 additional 800-μg doses at 14-day intervals and 32 weeks off study medication. Study 2 was a phase 2a, multicenter, single-arm trial enrolling 37 participants. ATX-MS-1467 was titrated from 50 μg i.d. on day 1 to 200 μg on day 15 and 800 μg on day 29 followed by biweekly administration of 800 μg for 16 weeks and 16 weeks off study medication. Efficacy was evaluated on MRI parameters and clinical variables. Safety endpoints included treatment-emergent adverse events and injection-site reactions. RESULTS: In study 1, there was a significant decrease in new/persisting T1 gadolinium-enhanced (GdE) lesions in cohort 1 from baseline to week 16, returning to baseline values at week 48. In study 2, the number of T1 GdE lesions were significantly reduced on treatment and remained reduced at study completion. Safety results were unremarkable in both studies. CONCLUSION: Relatively slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated with reduction in GdE lesions and a sustained effect post treatment. Further trials of ATX-MS-1467 are warranted. CLASSIFICATION OF EVIDENCE: This work provides Class IV evidence that for patients with relapsing multiple sclerosis, slow ATX-MS-1467 titration and a longer full-dose i.d. treatment period is associated with reduction in GdE lesions.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Chataway J, Martin K, Barrell K, et al. Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis. Neurology. 2018. PMID: 29467307. doi:10.1212/WNL.0000000000005118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。